» Articles » PMID: 16757701

Human Papillomavirus Testing and Liquid-based Cytology: Results at Recruitment from the New Technologies for Cervical Cancer Randomized Controlled Trial

Abstract

Background: Although testing for human papillomavirus (HPV) has higher sensitivity and lower specificity than cytology alone for detecting cervical intraepithelial neoplasia (CIN), studies comparing conventional and liquid-based cytology have had conflicting results.

Methods: In the first phase of a two-phase multicenter randomized controlled trial, women aged 35-60 years in the conventional arm (n = 16,658) were screened using conventional cytology, and women in the experimental arm (n = 16,706) had liquid-based cytology and were tested for high-risk HPV types using the Hybrid Capture 2 assay. Women in the conventional arm were referred to colposcopy with atypical cells of undetermined significance (ASCUS) or higher and those in the experimental arm were referred with ASCUS or higher cytology or with a positive (> or = 1 pg/mL) HPV test. Sensitivity and positive predictive value (PPV) for detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) were calculated.

Results: The screening methods and referral criterion applied in the experimental arm had higher sensitivity than that in the conventional arm (relative sensitivity = 1.47; 95% confidence interval [CI] = 1.03 to 2.09) but a lower PPV (relative PPV = 0.40; 95% CI = 0.23 to 0.66). With HPV testing alone at > or = 1 pg/mL and at > or = 2 pg/mL, the gain in sensitivity compared with the conventional arm remained similar (relative sensitivity = 1.43, 95% CI = 1.00 to 2.04 and relative sensitivity = 1.41, 95% CI = 0.98 to 2.01, respectively) but PPV progressively improved (relative PPV = 0.58, 95% CI = 0.33 to 0.98 and relative PPV = 0.75, 95% CI = 0.45 and 1.27, respectively). Referral based on liquid-based cytology alone did not increase sensitivity compared with conventional cytology (relative sensitivity = 1.06; 95% CI = 0.72 to 1.55) but reduced PPV (relative PPV = 0.57; 95% CI = 0.39 to 0.82).

Conclusions: HPV testing alone was more sensitive than conventional cytology among women 35-60 years old. Adding liquid-based cytology improved sensitivity only marginally but increased false-positives. HPV testing using Hybrid Capture 2 with a 2 pg/mL cutoff may be more appropriate than a 1 pg/mL cutoff for primary cervical cancer screening.

Citing Articles

HPV-Related Cancers in Bosnia and Herzegovina: A Comprehensive Review.

Paric A, Tomic K, Alidzanovic L, Fojnica A, Vranic S Acta Med Acad. 2024; 53(3):237-273.

PMID: 39655353 PMC: 11831570. DOI: 10.5644/ama2006-124.458.


Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.

Ostrbenk Valencak A, Kroon K, Fabjan D, Mlakar J, Seme K, Berkhof J Int J Cancer. 2024; 156(4):788-801.

PMID: 39315642 PMC: 11661515. DOI: 10.1002/ijc.35200.


Clinical Validation of the Vitro HPV Screening Assay for Its Use in Primary Cervical Cancer Screening.

Bellosillo B, Ibanez R, Roura E, Monfil L, Asensio-Puig L, Alvarez I Cancers (Basel). 2024; 16(7).

PMID: 38611001 PMC: 11011158. DOI: 10.3390/cancers16071322.


Human Papillomavirus-Associated Tumor Extracellular Vesicles in HPV Tumor Microenvironments.

Gameiro S, Flondra K J Clin Med. 2023; 12(17).

PMID: 37685735 PMC: 10488665. DOI: 10.3390/jcm12175668.


High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting.

Fleider L, de Los Angeles Tinnirello M, Gomez Cherey F, Garcia M, Cardinal L, Garcia Kamermann F PLoS One. 2023; 18(2):e0279728.

PMID: 36745662 PMC: 9901754. DOI: 10.1371/journal.pone.0279728.